标题
Systematic review: colitis associated with anti-CTLA-4 therapy
作者
关键词
-
出版物
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 42, Issue 4, Pages 406-417
出版商
Wiley
发表日期
2015-06-15
DOI
10.1111/apt.13281
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
- (2014) M. Aglietta et al. ANNALS OF ONCOLOGY
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
- (2014) Caroline Jochems et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA-4 polymorphisms and susceptibility to inflammatory bowel disease: A meta-analysis
- (2014) Young Ho Lee et al. HUMAN IMMUNOLOGY
- Association of CTLA-4 variants with susceptibility to inflammatory bowel disease: A meta-analysis
- (2014) Min Zhang et al. HUMAN IMMUNOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Ipilimumab-Associated Colitis: CT Findings
- (2013) Kyung Won Kim et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Ipilimumab-induced Perforating Colitis
- (2013) Kisha A. Mitchell et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2
- (2013) Chelsea Ma et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
- (2013) Vafa Shahabi et al. Journal of Translational Medicine
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Ipilimumab-induced acute severe colitis treated by infliximab
- (2013) Cecile Pagès et al. MELANOMA RESEARCH
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Ipilimumab-Induced Colitis on FDG PET/CT
- (2012) Ashima Lyall et al. CLINICAL NUCLEAR MEDICINE
- Abatacept for Crohn's Disease and Ulcerative Colitis
- (2012) William J. Sandborn et al. GASTROENTEROLOGY
- Drug-Induced Inflammatory Bowel Disease and IBD-Like Conditions
- (2012) Marie-France Dubeau et al. INFLAMMATORY BOWEL DISEASES
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
- (2012) Antoni Ribas et al. Journal of Translational Medicine
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Colitis associated with biological agents
- (2012) Hugh James Freeman WORLD JOURNAL OF GASTROENTEROLOGY
- Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma
- (2012) Stephanie Andrews et al. Cancer Management and Research
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
- (2011) Ahmad Tarhini et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Blockade of Cytotoxic T-lymphocyte Antigen-4 by Ipilimumab is Associated with a Profound Long-Lasting Depletion of Foxp3+ Regulatory T Cells: A Mechanistic Explanation for Ipilimumab-Induced Severe Enterocolitis?
- (2011) S. Nancey et al. INFLAMMATORY BOWEL DISEASES
- Lymphocytic Colitis Secondary to Ipilimumab Treatment
- (2011) Alejandro García-Varona et al. INFLAMMATORY BOWEL DISEASES
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
- (2011) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of cytotoxic T lymphocyte associated antigen-4 gene (rs60872763) polymorphism with Crohn's disease and high levels of serum sCTLA-4 in Crohn's disease
- (2011) Zhitao Chen et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer
- (2011) Grazia Graziani et al. PHARMACOLOGICAL RESEARCH
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
- (2010) Anna Maria Di Giacomo et al. SEMINARS IN ONCOLOGY
- Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
- (2009) David R. Minor et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
- (2009) James D. Lord et al. DIGESTIVE DISEASES AND SCIENCES
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
- (2008) R. L. Johnston et al. DIGESTIVE DISEASES AND SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search